Business and Finance

Cold Chain

Commercial Channels

Data and Technology

Legal and Regulatory

Manufacturing & Packaging

Market Access and Pricing

Opinion

Patient Support

Security

Supply Chain Logistics

Trade & Channel

News

Pharma Pulse

Publications

Brand Insights

Webcasts

Resources

Conferences

Conference Coverage

Conference Listing

Events

Videos

Podcasts

Editorial Podcasts

Subscribe

Business strategies and top news in the biotech / biopharma industry, including market access, supply chain distribution and more.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Commerce

Instagram

Facebook

LinkedIn

Threads

Soundcloud

Spotlight

Digital Editions

Topics

1rem

Articles

New Pharma Commerce column addresses the relevance of pricing.

Introducing Value & Access 

Semiannual update includes better revenue forecasting and state reporting

Model N Updates Its Revenue-Management Solution for Commercial Pharma Practices

Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies

The IRA is Industry's Wake-up Call

Agreement featuring UK pharma services consultancy intends to grow PharmaLex's pan-European market access presence

PharmaLex Merges with NeoHealthHub

While all drug development efforts are fraught with peril, a growing number of biopharma companies—large and small—are staking a claim in the rare disease treatment space, chasing odds that could yield clinical and financial rewards 

Betting the House on Orphan Drugs

 interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into:

How PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach

The platform’s biggest goal to when it comes to CHEORS and market access services

How CHEORS helps navigate cost-effectiveness and market access hurdles

Acquisitions in the space that are currently in the works

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

Navigating Market Access Hurdles

 interview, Brandon Newman, Xevant’s CEO and founder, explores:

The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system

The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved

How Xevant helps improve drug cost transparency efforts

Strategies for affordability Newman would offer the pharma industry that can be implemented immediately

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency. 

A Further Examination of Pharmacy Benefit Managers

By 2050, study estimates that cancer incidence and mortality rates will nearly triple in low-Human Development Index countries, highlighting an urgent need for enhanced global cancer prevention, early detection, and treatment strategies to address growing disparities.

Global Study Warns Cancer Cases to Triple in Low-HDI Countries by 2050, Urging Enhanced Prevention, Care Initiatives

Tips for pharmacies with the reimbursement blues.

Dusting Off One’s Cost Center Hat

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients. 

Medicare Part D: Navigating Plans and Potential Gaps in 2025

Analysis finds that while basic Part D coverage costs have decreased by 4%, mid- and high-tier plans have seen hikes of 4% and 21%, respectively. 

Report: Medicare Part D Premiums Rise an Average of 11% Nationwide 

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

Community Pharmacies in Crisis: Navigating the Challenges and Closures

Pharmacy Benefit Management Trends

, Albert Thigpen, co-founder, Talentwise Consulting, discussed how the panel on “Playing the Chess Endgame–Healthcare Policies Targeting Drug Commercialization” underscored the complexities of implementing the Inflation Reduction Act (IRA), predicting significant challenges for stakeholders like retail pharmacies, payers, and pharmacy benefit managers. They highlighted concerns about the unintended consequences of negotiated maximum fair prices (MFPs), particularly on the generics industry and oncology drug distribution, which could complicate decisions for companies and affect in-office dispensing practices. Overall, the panelists noted that the IRA's intricate framework might lead to unforeseen difficulties in the healthcare landscape.

Thigpen also emphasized the importance of taking a long-term and measured perspective for manufacturers when it comes to strategic approaches to pricing and commercialization in light of future US. healthcare policies. He noted that, similar to the evolving landscape of Medicare Part D over the past 20 years, the Inflation Reduction Act (IRA) will also undergo significant changes. Manufacturers should prepare for initial challenges and be ready to reassess their strategies annually, adapting to new rules and market dynamics as they emerge. This approach may involve delaying product launches or adjusting commercialization tactics based on negotiated MFPs and market conditions, akin to the strategies seen with AbbVie and Humira. Beyond that, Thigpen dove into key trends impacting the pharmacy benefit management and specialty pharmacy spaces, while providing a crash course on retail consumerism.

A transcript of Thigpen’s conversation with

Could you describe some of the key trends that are impacting the pharmacy benefit management space?

I think there are a couple of things. I think regarding the PBM benefit by itself, you have split it into two buckets. I view the PBM benefit of the vertically integrated companies very differently than the PBM benefit of a non-vertically integrated company. Just to be clear on what those are, the vertically integrated companies are those that are also tied to a rather large insurance carrier: UnitedHealthcare and OptumRx has integrated; Cigna and Express Scripts have integrated; Aetna and CVS are integrated; the true vertically integrated companies that do that, they view that very differently.

The pharmacy benefit continues to be our first line of defense for treating disease states across the board. I'm a pharmacist by training, and I love the pharmacy benefit, but it has become incredibly commoditized over the course of the years, but it's also a very valuable piece of the healthcare benefit architecture. Those vertically integrated companies, specifically in the government space, have figured out a way where they can lose money in the pharmacy benefit, but also be much more profitable in the medical space. A company like United, for example, can say, “hey Nico, I'm going to cover you as your medical carrier and also provide your prescription drug coverage through OptumRx. The premiums I'm charging you, in total, I could actually do quite well onm even though I may not be doing quite well on the pharmacy side.” Those vertically integrated companies have the ability to manage to spend very differently than a standalone PBM that is just out there, only surviving and trying to operate their business on prescription benefit drugs alone.

I think that on the surface, those two business models had very different mechanics in their trends by themselves. I think overall, cost continues to decline in general. There are still a ton of generics that continue to be very important to the pharmacy benefit. Specialty continues to be a large driver of the spend. More drugs are in the FDA pipeline that are specialty and/or rare orphan, ultra-orphan drugs that are incredibly expensive across the board. How we figure out the best coverage mechanisms for specialty, biosimilars, rare orphan, ultra orphan—these are key issues and trends that everyone is focused on. Then I would say, just as another benefit design trend, is that the cash markets continue to thrive here. Bill Roth alluded to it in his opening comments that companies like GoodRx or Mark Cuban’s Cost Plus Drugs and the like, are there for a reason. The cost or the cash pay marketplace is important because you can get drugs pretty affordable through a cash benefit, much cheaper than sometimes your drug benefit that is covered, which is something that is going to continue to rise. It plays into the knowledge and the power of the consumer, and ultimately what’s best for them.

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space. 

Latest Conference Coverage

Access Insights 2024: Pharmacy Benefit Management Trends

Reassessing Pricing and Commercialization Approaches

How can one strategically reassess pricing and commercialization approaches in order to anticipate the future US healthcare policy environment?

I think it's a couple things. If I were in a manufacturer’s shoes, you have to take the long game here. You’ve got to remember that in 2026, we would have 20 years of experience of the Medicare Part D benefit underneath our belts of expertise, and how it was originally intended to roll out is not how it looks in 2026 today, and that is because every year, the federal government allows for rule changes, business model changes, and open comment periods, and that is a fluid dynamic that evolves the program over time. I say that as context, because the IRA [Inflation Reduction Act] today is going to look like a one-year snapshot in time—it's not going to be the greatest implementation out of the gate, and it will continue to evolve.

With that in mind, the manufacturers have got to take a very long view and maybe a conservative view out of the gate. They should say, “I know this isn't going to be perfect, and I know I may lose on some and win on some others, but I've got to maybe take a measured approach to the business and continually reassess it every year.” The payers are going to do the same, the PBMs are going to do the same, the retail markets and the distributors will all do the same. They can only play the cards that they're dealt in year one, then they reassess, they re-evaluate, and then wait for rule changes to occur. They kind of figured out that plan, and lo and behold, over time, we figured out somehow to make Medicare Part D successful in 20 years.

I suspect that will be some of the same cadence with the IRA and the drug manufacturers, but I do think it changes the dynamic of where the manufacturer needs to focus. For example, being fully ready to launch on day one of the PDUFA [Prescription Drug User Fee Act] date when they launch and being ready to commercialize. Then, I follow this product life cycle, and maybe, if there's an MFP [maximum fair price] tied to a drug that I'm subject to, maybe a generic doesn't launch it, maybe I need to continue to ride that out and extend that product life cycle for a period of time. It’s similar to what we've seen AbbVie and Humira exercise with biosimilars, so I think it's a measured approach. I think it is a one-year reassess every time, every year, but knowing that the rules are going to change [I would], tread lightly this year.

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Access Insights 2024: Reassessing Pricing and Commercialization Approaches

Key Nuggets Surrounding the Chess Endgame

What were the main nuggets that came out of your “Playing the Chess Endgame–Healthcare Policies Targeting Drug Commercialization” panel?

I think probably the biggest takeaway is that the IRA is complicated. The implementation of it is going to be super complex. I think the panel universally agrees that the implementation of the IRA that has implications on the retail pharmacies, the payers, the patients, the PBMs, in general, hasn't quite been architected in the way for success, and we're just planning on some train wrecks, as we had referred to it in the panel. I think that's the first thing.

The second thing is that the MFPs that have been negotiated as a result of the IRA are going to have some unintended consequences across the board to other constituents—for example, the generics industry. How does a generic company decide to launch or not launch because the MFP has already been negotiated to a very low point already, and what are the unintended consequences of that? Negotiating an MFP on an oncology drug: going forward, how much does that impact, or have an unintended consequence of a physician that does in-office dispensing? I think for the vast, high level, I would say the IRA is complex. It's not fully thought out of all the consequences that will occur. We're starting to figure out some of those solutions, but very murky waters as we know it today.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

Access Insights 2024: Key Nuggets Surrounding the Chess Endgame

Access Insights

PC: What other sessions at the conference have you found to be the most interesting?

Well, I've been very impressed, and it certainly has fed my inherent pessimism, with the discussion about retail pharmacy, particularly as a sort of uniquely challenged aspect of the supply chain. Bill Roth had an absolutely fantastic presentation to lead off that really scoped out the many challenges and just how significant those challenges are. His takeaway was that we are really reverting to an almost pre-World War II world in which services are based on cash increasingly, and where compounding is a bigger and bigger part of the delivery of drugs to patients. But those were some really important observations there. A little later, there was a panel that talked about the state of retail pharmacy from a number of different perspectives, including large chain pharmacies, and even those big players are under huge pressure to innovate great drugs and get them through the FDA process. You can theoretically even create coverage and reimbursement for them at the payer level. But if there's not actually a means to deliver those drugs to patients, you've got a huge problem and the degree of pressure that retail pharmacies are under, certainly the independence, but even really the chains are a disturbing component of what we're facing as an industry right now.

 The implementation of the Inflation Reduction Act is expected to be challenging, with both short-term losses and operational difficulties. While the Act aims to help patients through measures like a $2,000 out-of-pocket cap and a smoothing mechanism, it may also lead to higher premiums and deductibles. Additionally, the negotiated prices might not yield the expected savings, and there could be negative consequences for biosimilars, generic drugs, and pharmaceutical innovation.

Retail pharmacy is facing significant challenges, including a potential return to a cash-based system and increased compounding. Even large chains are under pressure, impacting patient access to treatments. Other factors affecting patient access include the potential for plans and PBMs to move away from negotiated price drugs, maximizers and accumulators, and alternative funding programs involving unapproved drugs. These issues collectively pose a significant threat to patient access to treatments.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses other standout sessions at this year’s Access Insights conference.

Access Insights 2024: Notable Breakout Sessions

Chess Endgame

PC: You were recently on a panel entitled “Playing the Chess Endgame: Healthcare Policies Targeting Drug Commercialization.” What are the main points that the audience should take away from that presentation?

I think unfortunately, the implementation of the Inflation Reduction Act is going to be a bumpy thing, are going to be a lot of losers, at least in the short term, including patients. I think the panel was influenced by my pessimism. There were some optimists on the panel, but I was definitely the lead pessimist.

We saw some pretty significant challenges. Obviously, the statute is trumpeted as having a number of components that should help patients with a $2,000 cap on their out-of-pocket expenses over the course of the year. It’s a smoothing mechanism that will allow them to pay for their out-of-pocket costs on a smooth basis across the year. hose sound great, but unfortunately, they come with some countervailing pressures, such as higher premiums and deductibles for those patients who are under $2,000 in co-payments and co-insurance.

We also talked about some of the operational challenges that will be involved here, and I think the panel thought there were a lot of significant operational challenges. Those include whether or not the idea of having negotiated prices really are going to yield the kind of savings that MS is expecting them to, or whether plans and PBMs may actually push patients away from those drugs to high list, high rebate alternatives, whether the dynamic that's being created here will have a pretty detrimental impact on biosimilars and generic drugs generally, whether we could be on the threshold of an environment in which pharmaceutical innovation is negatively impacted. As a rare disease patient, that’s a huge source of concern for me. There are things in the IRA that are designed to make sure that rare disease development programs are not as adversely affected as other drug programs, but I don't have much confidence in those provisions, and I'm afraid that we're already seeing some very significant and negative consequences for innovation.

: The implementation of the Inflation Reduction Act is expected to be challenging, with both short-term losses and operational difficulties. While the Act aims to help patients through measures like a $2,000 out-of-pocket cap and a smoothing mechanism, it may also lead to higher premiums and deductibles. Additionally, the negotiated prices might not yield the expected savings, and there could be negative consequences for biosimilars, generic drugs, and pharmaceutical innovation.

William Sarraille, professor, University of Maryland Francis King Carey School of Law, discusses breakout session and the impact of healthcare policies on manufacturing and commercialization. 

Access Insights 2024: Playing the Chess Endgame: Healthcare Policies Targeting Drug Commercialization

Interview with Blake Powers, Part II

: With pharmacies being under pressure to lower drug-acquisition costs, how can digital formats help manufacturers better manage price based on real-time data?

 I'll start from really the pharmacy side. So pharmacy departments, whether you're a retailer or at a big integrated delivery network, they're responsible for their own P&L—their profit and loss statement—and most are leveraging strategies with revenue cycle management and reimbursement strategies, but now they're looking to the other side of the equation in terms of, what can I do from a non-labor perspective that's going to help me with my cost? And that's drug acquisition cost management. So there's definitely the pressure from the site of care perspective and pharmacy perspective to see what are some go-get goals for 2024, or the next fiscal year.

Now, from the lens of somebody in a trade function role at a pharma manufacturer—and you're maybe selling injectables into a hospital or maybe a new biosimilar has just been released. Chances are, you're probably choking on the price tags of your distribution fees, and you're concerned whether or not you're going to be able to land at a competitive price for each and every hospital, or retail pharmacy, and that's where having NDC-specific price dexterity via these digital distribution kind of models and platforms, really puts manufacturers in a better position to be nimble, to adjust when necessary, and really stay competitive. And I think, all-in-all, the theme of the piece is: doesn't that really help with the supply chain resiliency, if we have an atmosphere and environment where more and more pharma companies feel like they can compete in the space, not not just with price, but also with levels of service, with reliability, and the quality of the product? I

 What is the likelihood of NDC-specific price dexterity via these digital distribution models and platforms taking effect?

 I'm already seeing some success with my platform, Medigi, so it's having success with certain product archetypes, particularly ones that are going direct. You have generics, you have biosimilars, and specialty light product archetypes that are already trending direct, and especially when manufacturers think of it from an NDC specific mindset; it may not be applicable to their full portfolio, but there's probably certain products where they're wanting additional pull through, they're wanting increased market penetration, and they're trying to consider different avenues and direct product pathways for providers to have an optimal user experience when it comes to sourcing their treatments. We're already seeing signs of evidence that it is working, so it'll be interesting to see to what extent it's adopted in the space.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, explains how digital formats help manufacturers better manage price based on real-time data, along with the impact of NDC-specific price dexterity.

Helping Manufacturers Better Manage Price

Interview with Blake Powers, Part 1

: You recently penned your first byline, which has appeared in the June issue of 

 What I'm doing here in the first write up is really contemplating digital platforms and dynamic pricing models, and what they've accomplished in other sectors. And really having an objective look about what it might appear if these technologies are applied to the pharma supply chain—taking a bit of a contrarian approach to some of the status quo models, and kind of looking at it from another angle and seeing what have other sectors accomplished from this kind of innovation and this dexterity with pricing, and how might it be applied to the pharma supply chain?

 Why do you believe the pharma sector is stuck in its ways, in terms of depending on older models that rely on long-term price negotiations that lock in prices?

 I think a major reason is that fragmentation in this sector is naturally creating an uphill battle for any change agent that's entering the space. In terms of looking at what other commodities and services have accomplished with dynamic pricing in these digital platforms, I think it is important to take a closer look at medications and how they're distributed. There's a certain degree of scrutiny that certainly needs to be applied, because these are life-sustaining and life-saving medications. However, in the piece, I take the stance that the status quo models have their shortcomings, and I try to highlight the benefits, and take that position of, what would digital models taking a free-market type of approach, what kind of benefits would they have for pharmacies, sites of care, and drug manufacturers?

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi,  discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.

Exploring the Concept of Dynamic Pricing 

US Drug Price Decrease

PC: Do you believe it's feasible for drug prices to be lowered in the US?

There have been cases where companies have exploited it. Particularly, it has happened for older drugs. Only one company produces it and then they hike the costs. That's not very ethical behavior and we should all be be against that. But that's not what the general trend is in the marketplace in the US. Can you lower prices? Yes, of course you can. You can make it as low as you want, but will somebody still be able to produce it and come up with new innovations? No, of course not. It has to come from somewhere. 

PC: Are there any other future article topics that you can share with the audience?

A couple of topics come to mind. The Inflation Reduction Act: we need to see how the IRA works out negotiations that are ongoing. Everyone is looking at that. But then also on the theme that we just talked about, right? With respect to what price controls are happening in other markets specifically. But also, what is the sustainability in our environment?  I mean, we're complaining about affordability right now. There was just another gene therapy that was declared to be worth $3.9 million. Those are amazing amounts, for frankly, amazing treatments, of course, with a very small patient population. That's why it doesn't work any other way, unfortunately. But new technology is advancing. There will be more expensive treatments. So there is a point where we just have to have that ethical discussion. I mean, how are we going to deal with that? if we have these great innovations, but we cannot afford to give them everybody, that's a difficult question. We need to comes to grips with that if innovation goes further. So let's hope we have that problem. How do you address that that affordability aspect? In Europe, governments are really clamping down much harder on prices, but also in emerging markets. There's a huge issue in African and Asian countries when it comes to access to cancer medicines. WHO paid a lot of attention to this until the beginning of COVID. But it's still an issue that is there. How do we address that? What are the consequences of that? If you supply a drug to a poor country, Is the US public going to accept that? Is the European public going to accept that? These are very complex societal issues in a world where there's so much conflict and war. How can you expect governments to get together to solve that? he industry is kind of caught in an area where they need to handle that, but there's no political stage to have that conversation.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value & Access Advisor, Schoonveld Advisory, offers his thoughts on lower drug prices in the US and provides a sneak peak into future PC features. 

Ed Schoonveld Discusses Drug Pricing in the US and Upcoming Articles

Ed Schoonveld List Prices

PC: You recently penned your latest byline for the April issue of 

. Without giving too much away, what does it discuss?

The congressional hearings led by Bernie Sanders were a reason to pick up the topic of drug pricing again, which continues to be a big issue in the US. So I felt I needed to comment on that, and I'm calling it "In Search of the 'Bad Guy.'" I really think that we keep searching for the bad guy, but maybe there's no bad guy, maybe we just have a societal issue. That's a topic that goes very near and dear to my heart that I talk about in this article as well. 

PC: Why are US list prices for prescription drugs often higher than in other countries, and what should be done to lower these prices?

We need to distinguish between price and cost to the patient. Prices have gone up as technology has gone up, but prices to patients have gone up much more than that. Insurance companies have shifted more of the cost to patients, so they've become more sensitive to it. That's problematic, particularly when patients can't afford it. Yes, cost has gone up, but technology has advanced. As a matter of fact, drug cost has not gone up more than other health care costs. It's still at a constant 12% to 13% over the last 20-25 years. That still can make it a problem, of course, for an individual patient and that's where we need to focus. Why is it more expensive than let's say, for example, Europe? Well, that's a bit of a double edge. In Europe, governments are controlling price. Some say we should control price as well. But you know, when somebody steals my car, the answer is not to steal somebody else's car. I just think that government should probably help the industry more. I'm using an example in my article of the UK, where the dollar value of a drug has not gone up, not adjusted for inflation in 20 years. So I think we need to just keep a good look at what's happening in other countries and why the prices are so high in the US. Now when you when you're talking purely economically, it's not optimal to have every global citizen pay the same price for a product. It is economically optimal to adjust it by affordability. If we insist that prices in the rest of the world are just as high as in the US, particularly in poor countries, nobody would be able to buy it, so it would stay on the shelf. That means that the US would have to contribute more to the overhead costs. So prices would actually have to go up more here. I know that's not a happy answer, but economically speaking, we are better off to have drugs priced at affordability in each country so that each individual can contribute towards the overall cost of R&D, medical infrastructure, etc. So if we could just stop looking for the bad guy and look at the issue, I think we would be much better off.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, Value and Access Advisor, Schoonveld Advisory and author of The Price of Global Health, explains why pharmaceutical products tend to cost more in the US than the rest of the world. 

Ed Schoonveld Discusses List Prices for Pharmaceuticals in the US Compared to Other Countries

Corey Ford IRA Future

PC: How do you believe the IRA will evolve over the next five to 10 years?

There's a lot of different thoughts out there in terms of where we see IRA going. Do we see several tweets? o we see major changes and overhauls to the law itself? Or do we see it even go away completely whether we have a sea change in terms of the political dynamics in Washington starting next year post the election? Does the lawsuit get rid of the Medicare negotiation program?

I think there's a wide spectrum here in terms of what can happen. But if I had to pick, think what you're going to see is probably some additional fixes and tweaks to the law, trying to enhance patient access to minimize some of the unintended consequences for Medicare beneficiaries. Also, trying to get patient engagement through the negotiation process as well. That’s where I think you'll see a lot of changes to the law. We have some proxies to previous legislation to help us think this through.

There have been numerous legislations before in the past in the pharmaceutical space that has really tried to spur on innovation, when we think of things like the Orphan Drug Act, or even Hatch Waxman. Even within these major landmark acts that have been passed in Congress, there's been follow up legislation to further refine them. Even if we don't necessarily see refinement in Congress with IRA, I think we certainly could see that from a regulatory standpoint to help minimize some of the negative impact for some of these unintended consequences that I've mentioned and what it means for patients.

PC: Next month, you’ll be kicking off the PAP 2024 conference with a presentation titled: “State of the Industry—The Changing Landscape of Healthcare Coverage and Access.” Without giving away too much information, can you tell us what to expect from your speech?

I won't give too much away; it's going to be a lot of fun. From what we’ll focus on, a good portion of it will be IRA and where we're seeing the patient support programs going in terms of their criteria and how to educate beneficiaries. Regarding some of the other topics we’ve discussed in the past, there's been a lot of developments in copay accumulators and what’s happened from a recent court ruling. We’ll tackle access to health insurance. The Medicaid unwinding, due to the public health emergency ending to things like the PDM Transparency Act and what that means for patient access. We’ll also be trying to crystal ball a little bit with the election, where that could go and what it means for health policy. So, we’ll cover those.

The theme of it will be when we think about what's happening in the world, right, it feels chaotic, right? You look at all the polling, and it seems like the country is on the wrong direction. You also apply what is going on in the industry. In terms of the public the negative perceptions, according to polling that the public has on pharma, the layoffs, and the reduced resources that industry is facing, it paints a picture of a pretty tough environment. But I think it's also important for us to understand that there is some hope out there. It begins with the people that are going to be in that audience. As patient support folks, they’re the last line of defense. They’re on the front lines of ensuring that patients can get access to a therapy when everything else has failed. Also, what are the tactics that you can put forth to continue supporting patients?

That’s what we want people walking away with, a feeling of being able to do this, and to at least be equipped with some of those ideas for how to evolve their patient support programs to effectively support their patients.

In an interview with Pharma Commerce Associate Editor Don Tracy, Corey Ford, VP, Reimbursement & Policy Insights, Cencora, offers his thoughts on where the Inflation Reduction Act will be five to 10 years from now. 

Market Access and Pricing

Latest News

More News